BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21328450)

  • 1. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
    Zulehner N; Maurer M; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
    Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
    Wesierska-Gadek J; Borza A; Komina O; Maurer M
    Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Schmitz ML; Ranftler C
    J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
    Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
    J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
    Maurer M; Komina O; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Kramer MP; Maurer M
    Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Gueorguieva M; Herbacek I; Ranftler C
    Ann N Y Acad Sci; 2007 Jan; 1095():45-52. PubMed ID: 17404016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
    Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
    J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
    Wesierska-Gadek J; Maurer M; Schmid G
    J Cell Biochem; 2007 Oct; 102(3):736-47. PubMed ID: 17415788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
    Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
    J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
    Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
    Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
    Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
    Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.